Alexander Nyström

Principal Investigator

Department of Dermatology
Medical Center – University of Freiburg

Hauptstrasse 7
79104 Freiburg i. Brsg.

Current position

Group leader, Department of Dermatology, Medical Center – University of Freiburg

Academic training

1997 – 2002 Study of Molecular Biology at Lund University, Lund, Sweden

Scientific qualifications

2006 Dissertation in Developmental Biology, Lund University, Sweden

Postgraduate Positions

since 2013 Group leader, Department of Dermatology,
Medical Center - University of Freiburg
2010 – 2012 Postdoctorate, Department of Dermatology,
Medical Center - University of Freiburg
2007 – 2009 Postdoctorate, Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA

Miscellaneous (Honors, Awards)

2021 - 2022 Internal Senior Fellow – Freiburg Institute for Advanced Studies
2016 Rupert Timpl Award International Society For Matrix Biology

link to all publications from A. Nyström: Pubmed

Publications based on CRC1160 funding

Susana Minguet, Alexander Nyström, Dimitra Kiritsi, Marta Rizzi. 2022. Inborn errors of immunity and immunodeficiencies: Antibody-mediated pathology and autoimmunity as a consequence of impaired immune reactions. Eur J Immunol, First published: 20 April 2022; doi.org/10.1002/eji.202149529

Schauer F, Nyström A, Kunz M, Hübner S, Scholl S, Athanasiou I, Alter S, Fischer J, Has C, Kiritsi D. 2022. Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita. Front Immunol. 13:883967.  doi: 10.3389/fimmu.2022.883967.

Nyström A, Bruckner-Tuderman L, Kiritsi D. 2021. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet. 12:737272. doi: 10.3389/fgene.2021.737272. eCollection 2021.

Bernasconi R, Thriene K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth A-C, Stumpe M, Kiritsi D, Martin SF, Hinz B, Bruckner-Tuderman L, Dengjel J, Nyström A. 2021. Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7). EMBO Mol Med. e14392.

Akasaka E, Kleiser S, Sengle G, Bruckner-Tuderman L, Nyström A. 2020. Diversity of Mechanisms Underlying Latent TGF-β Activation in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. S0022-202X(20)32357-5. doi: 10.1016/j.jid.2020.10.024. Online ahead of print.

Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. 2020. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.  J Invest Dermatol. S0022-202X(20)32061-3. doi: 10.1016/j.jid.2020.08.018. Online ahead of print.

Nyström A, Kiritsi D. 2020. Transmembrane collagens – unexplored mediators of epidermal-dermal communication and tissue homeostasis. Exp Dermatol. doi: 10.1111/exd.14180. Online ahead of print.